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ABSTRAK ABSTRACT
Tujuan: mengetahui hubungan antara faktor-faktor prognostik
kanker ovarium dengan kesintasan tiga tahun pasien kanker
ovarium epitelial.
Bahan dan Metode: Penelitian kohort retrospektif pada 90 pasien
(selama tahun 2012) di RSUP Dr. Kariadi. Kaplan Meier, Log
rank, dan Cox regresi digunakan untuk menganalisa kesintasan
dan faktor prognostik yang berhubungan dengan penyakit ini.
Hasil: Kesintasan 3 tahun pasien kanker ovarium epitelial secara
keseluruhan adalah sebesar 58,5% (Kaplan Meier). Kesintasan 3
tahun pasien kanker ovarium epitelial adalah sebesar 89,3%,
44,4%, dan 35,1%, pada pasien dengan stadium I, stadium II, dan
stadium III secara berurutan, dan tidak ada pasien yang bertahan
hidup hingga 3 tahun pada stadium IV. Faktor prognostik yanng
berhubungan dengan kesintasan 3 tahun pasien kanker ovarium
epitelial yaitu stadium, asites, residu tumor, dan jenis
histopatologi {p<0,001; p=0,001; p=0,004; p=0,041, secara
berurutan (uji Log rank)}, sedangkan usia dan ukuran tumor tidak
berhubungan. Setelah dilakukan analisis multivariat (Cox regresi),
hanya stadium yang berhubungan dengan kesintasan 3 tahun
pasien kanker ovarium epitelial.
Simpulan: Ada hubungan antara stadium, asites, residu tumor,
jenis histopatolog dengan kesintasan 3 tahun penderita kanker
ovarium epitelial. Stadium merupakan faktor prognostik yang
paling mempengaruhi kesintasan 3 tahun penderita kanker
ovarium epitelial pada penelitian ini.
Kata kunci: kanker ovarium epitelial, faktor prognostik,
kesintasan 3 tahun
Objectives: to determine the association between prognostic
factors of ovarian cancer with a 3-years survival rate of epithelial
ovarian cancer patients.
Material and Method: Retrospective cohort study was
conducted in 90 patients (during 2012) at Dr.Kariadi General
Hospital. Kaplan meier, Log rank and Cox regression were used
to analyse survival rate and prognostic factors that influence the
disease.
Result: Overall 3-years survival rate of epithelial ovarian cancer
patients were 58.5% (Kaplan meier). Three-years survival rates
were 89.3%, 44,4%, and 35.1% for patients in stage I, stage II,
and stage III, respectively, and no patient survive up to 3 years in
stage IV. Prognostic factors that associated with 3-years survival
rate were stage of the disease, ascites, residual tumor, and type of
histopathology {p<0,001; p=0,001; p=0,004; p=0,041,
respectively (Log rank test)}, whereas age and size of tumor were
not associated. After using multivariate analysis (Cox regression)
only stage of the disease was associated with 3-years survival rate
of epithelial ovarian cancer patients.
Conclusion: There were an association between stage of the
disease, ascites, residual tumor, type of histopathology, and 3-
years survival rate of epithelial ovarian cancer patients. Stage of
the disease was a prognostic factor that most influence 3-years
survival rate of epithelial ovarian cancer patiens in this study.
Keywords: epithelial ovarian cancer, prognostic factors,
3-years survival rate
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INTRODUCTION
Ovarian cancer is the leading cause of death in women
due to gynecologic malignancy.1 Ovarian Cancer is
called The Silent Lady Killer because it is difficult to
detect at an early stage so that it becomes the highest
cause of death in women. In 2012 there were 238,719
new cases of ovarian cancer in the world, and there
were 151,905 women die of ovarian cancer,2 Cases of
ovarian cancer in developed countries was 99,752 cases,
and in developing countries was 138,967 cases. While
in Indonesia alone the number of cases of ovarian
cancer was 10.238 and 7,075 were dead.3
The most frequently encountered types of ovarian
cancer is epithelial ovarian cancer (85% -90%), and
become the biggest cause of death from ovarian cancers.
Response to treatment of ovarian cancer can be
evaluated in conjunction with prognostic factors.
Prognostic factors of ovarian cancer are histopathology
of  tumor, differentiation of tumor cells, ploidy, stage,
volume of ascites, tumors size outside the ovaries before
cytoreduction, residual tumor after cytoreduction,
patient’s age, tumor response that is slow to chemo-
therapy, and performance status ( general state) .4
Favorable prognostic factor is the lower stage, well-
differentiated tumor cells, no residual tumor, good
general condition, and younger age. While poor prog-
nostic factors include the clear cell and serous type of
histology, advanced stage, the presence of ascites, the
presence of residual tumor and older age.5 The success
rate parameter of the treatment is survival after
treatment.
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This study aims to determine the relationship between
prognostic factors of ovarian cancer (stage, age, ascites,
tumor size, residual tumor and histopathologic type with
three-year survival of patients with epithelial ovarian
cancer.
MATERIALS AND METHODS
This study is an observational analytic study with
retrospective cohort design using secondary data from
medical records of patients. The entire epithelial ovarian
cancer patients who met the inclusion and exclusion
criteria were enrolled as the samples in this study (90
patients). Criteria for inclusion in this study were
patients who were diagnosed with epithelial ovarian
cancer in 2012, had surgery and received treatment at
the Hospital Dr. Kariadi (referral hospital for oncology
cases in Central Java). This study was conducted in May
2016.
The data of epithelial ovarian cancer patients who were
included in this study were taken and followed for 3
years from the date of diagnosis. The data taken were
the date of diagnosis, stage, age at diagnosis, presence
or absence of ascites before surgery, tumor size before
surgery, postoperative residual tumor, histopathological
type, date of death or date missing from observ-
ation. Then the tabulation and analysis of data were
done. Kaplan meier, log rank and Cox regression were
used to determine the survival of patients with epithelial
ovarian cancer and prognostic factors that influence it.
RESULTS AND DISCUSSION
The results of the data analysis in 90 patients with
epithelial ovarian cancer, who were operated at
Dr. Kariadi Hospital in 2012, resulted that there were 48
patients still alive up to 3 years of observation, 6
patients lost from observation and 36 patients died
before the end of the study. Based on Table 1, most of
the patients were in stage III (43.3%). More than half of
the patients (62.2%) were aged ≤ 51 years. Patients with
ascites were more than those without ascites. The size of
the tumor before surgery in most patients (57.8%) was>
500 cm 3. Patients that did not have postoperative
residual tumor were 88.9%. The most common histo-
pathological type was type of serous (40%). In this
study, the miscellaneous categoryof histopathology
was mixed cell types. From table 2 it can be seen that
the test results for the Kaplan Meier overall 3 years
survival of epithelial ovarian cancer patients at the
Dr. Kariadi Hospital Semarang was 58.5%.This result is
similar to a research at Dharmais Cancer Hospital
Jakarta stating that the 3-years survival of patients with
epithelial ovarian cancer was 56%. 6 Three years sur-
vival of epithelial ovarian cancer patients in developed
countries such as UK was 55.2%, and in Denmark was
50%.7.8 Three-year survival of patients with epithelial
ovarian cancer in developing countries such as Thailand
was 58.6%.9 All values are slightly lower when
compared with the results of this study and the
differences between3-years survival of patients with
epithelial ovarian cancer in developed countries and
developing countries was not too much.
Table 1. Characteristics of epithelial ovarian cancer
patients
Variables n %
Stages
 stage I
 stage II
 stage III
 stage IV
38
9
39
4
42.2
10
43.3
4.4
Age at diagnosis
 ≤ 50 years
 > 50 years
56
34
62.2
37.8
Ascites before surgery
 no ascites
 with ascites
42
48
46.7
53.3
Tumor size before surgery
 <10 cm3
 10-50 cm3
 > 50-200 cm 3
 > 200-500 cm 3
 > 500 cm 3
0
2
11
25
52
0
2.2
12.2
27.8
57.8
Postoperative residual tumor
 none
 ≤ 1 cm
 > 1 cm
80
10
0
88.9
11.1
0
Histopathological types
 mucinous
 serous
 endometrioid
 clear cell
 miscellaneous
31
40
5
10
4
34.4
44.4
5.6
11.1
4.4
3-year survival in stage I was 89.3%, 44.4% in stage II,
35.1% in stage III, andin stage IV there was no patient
who survived up to 3 years. Patients with stage IV
ovarian cancer (4 patients), survived for 7 days, 4 days,
3 days, and some even died before 24 hours post-
operatively (0 days). From these results it can be
concluded that the higher the stage, the lower the chance
of survival. Log rank test results showed significant
correlation (p<0.001) between stages with 3 years
survival. Research in Iran also showed a similar thing
with a value of p=0.0377.10
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Table 2. Analysis of three-year patient survival bivariate epithelial ovarian cancer
Variable KaplanMeier Log rank
Cox Regression
p HR 95% CI
Whole 0.585
Stage
- Stage I
- Stage II
- Stage III
- Stage IV
0.893
0.444
0.351
0
p < 0.001
0.000
0.004
0.000
0.000
1
6.782
8.707
208.399
1.816 - 25.327
2.993 - 25.329
36.954 - 1175,251
Age at diagnosis
- ≤ 50 years old
- > 50 years old
0.613
0.539
p=0.653
0.653
1
1.164 0.600 - 2.258
Ascites before operation
- No ascites
- Ascites
0.777
0.413
p=0.001
0.001
1
3.503 1.642 - 7.473
The size of tumor before operation
- <10 cm3
- 10-50 cm3
- >50-200 cm3
- >200-500 cm3
- >500 cm3
-
1
0.808
0.490
0.565
p=0.279
-
0.488
0.928
0.918
0.919
-
1
3306.529
10845.253
9331.904
0.000 - 7529.286
0.000 - 2458.389
0.000 – 2114,460
Residual Tumor
- No
- ≤ 1 cm
- > 1 cm
0.629
0.146
-
p=0.004
0.006
1
3.240
-
1.400 - 7.499
-
Histopathology type
- Mucinous
- Serous
- Endometrioid
- Clear cell
- Miscellaneous
0.804
0.427
0.400
0.667
0.500
p=0.041
0.066
0.005
0.086
0.452
0.117
1
3.648
3.370
1.704
0.726
1.477 - 9.012
0.842 - 13.493
0.425 - 6.823
0.726 - 17.857
Three-years survival rate in the age group ≤50 years was
61.3%, and> 50 years was 53.9%. Log rank test results
showed no significant correlation (p=0.653) between
age and 3 years survival. These results are in contrast to
the existing theory, but previous studies also showed no
significant result such as in RSKD with p=0.134, in Iran
with a value of p=0.613, and in Greece with value of
p=0.063.6,10,11
Three-years survival in patients without ascites was
77.7%, and with ascites was 41.3%. Log rank test
results showed significant correlation (p=0.001)
between the presence of ascites with 3 years survival,
where the presence of ascites would make survival
lower. Other studies also suggested that there was a
relationship between ascites with survival (p<
0.001).12 Epithelial ovarian cancer patients with ascites
had 3.503 greater risk of death compared to those
without ascites. The presence of ascites will increase the
risk of death.
The smallest size/ volume of tumors (10-50 cm3) had
the highest 3 years-survival that was 100% (2 pa-
tients). While the largest size of tumor’s(> 500 cm3) 3-
year survival rate was not the lowest(56.5%). 3-year
survival is the lowest in tumor size> 200-500 cm3 that
was 49% (25 patients). Log rank test results showed no
significant relationship (p=0.279) between tumor size
and 3 years survival. Not many research on tumor size
were associated with survival. Research on Progression
Free Survival defined the size of the tumor as the size of
the largest mass with categories of ≤ 10 cm and> 10
cmdiameter, and the log rank test results revealed no
correlation.13
Three-year survival rate in patients that were not
contained residual tumor was 62.9%, and in patients
with residual tumor (≤1cm) was 14.6%. Log rank test
results showed significant correlation (p=0.004)
between the residual tumor with 3 years survival, the
greater the residual tumor, the smaller the chance of
survival. The results of this study are similar to other
studies that found a strong link between residual tumor
with survival.14,15 Patients with residual tumor sized 0.1-
1 cm were at risk of dying 2.31 times greater compared
with patients who had microscopic residual tumor, and
patients with residual tumors >1 cm were at risk of
dying 2.45 times greater than patients who had
microscopic tumor residue.12 So the larger the residual
tumor, the greater the risk of death.
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Table 3. Multivariate analysis of three-yearssurvival in
epithelial ovarian cancer patients
Variables B p HazardRatio
95% CI for HR
Lower Upper
Stages
 Stage I
 Stage  II
 Stage  III
 Stage  IV
1.914
2.164
5.339
0.000
0.004
0.000
0.000
6.782
8.707
208.399
1.816
2.993
36.954
25.327
25.329
1175.251
3-year survival based on the type of histopathologywas
ranging from the highest to the lowest; mucinous
(80.4%), clear cell (66.7%), miscellaneous (50%),
serous (42.7%), and endometrioid (40 %). These results
are in contrast to the theory that histopathologic type
of clear cell has the highest incidence of recurrent with
the shortest survival so clear cell prognosis is generally
poor. 5,16 In this study, clear cell and serous had 3 years
survival better than endometriod , but still lower than
mucinous. The sequence is consistent with the theory
that the mucinous type of histopathology has better
prognosis than serous. 17 The results of this study were
similar to other studies which suggested that patients
with mucinous and clear cell type of histopathology had
better survival rate than the patients with serous
type. 18 The differences between the theoretical results
with the results of this study could possibly happen due
to lack homogenity of the sample. The sample in this
study used all stages of epithelial ovarian cancer.Maybe
the results will be more accurate in the same stage, for
example, only using samples of stage III. Log rank test
results showed no significant correlation (p=0.041)
between the type of histopathology with 3 years
survival.
Variables that could be included in the multivariate
analysis were the stage, ascites, residual tumor and
histopathologic types. In Cox regression test results,
only the stage variabel gave highly significantvalue,
with p <0.001. This means that ascites, residual tumor,
histopathological types variables influenced the survival
rate individually, but not cumulatively. Thus, the
prognostic factors that most influence the 3-years
survival rate of epithelial ovarian cancer patients is the
stadium.
Stage II epithelial ovarian cancer patients had mortality
risk 6.782 (95% CI 1.816 to 25.327) greater than stage I.
Patients with stage III epithelial ovarian cancer had the
risk of death increased 8.707 times (95% CI 2.993 to
25.329) greater than stage I. Patients with stage IV
epithelial ovarian cancer had risk of death 208.399
times (95% CI 36.954 to 1175.251) greater than stage I.
From these results it can be concluded that the higher
the stage, the risk of dying is higher.
The previous study also mentioned that the stage is a
prognostic factor in survival after multivariate
analysis.6,11,19 The results in RSKD Jakarta said
prognostic factors that most influence the survival of
epithelial ovarian cancer were stage, ascites,
hemoglobin and albumin.6 Prognostic factors that
affecting survival the most based on the results of
research in Greece was stage, residual tumor,
performance status, and tumor cell types.11 Research in
Germany said a prognostic factor that influenced
survival the most was the stage, residual tumor, age, and
peritoneal carcinomatosis.19
CONCLUSION
Three-years survival rate of epithelial ovarian cancer
patients overall was 58.5%. Prognostic factors
associated with3 years-survival of epithelial ovarian
cancer patients were clinical stage, ascites, residual
tumor and histopathologic types. Meanwhile age and the
size of tumor was not associated with 3 years survival of
epithelial ovarian cancer patients. Prognostic factors
that most influence the 3 years survival of epithelial
ovarian cancer patients was clinical stage, with a
survival rate of 89.3% for stage I, 44.4% for stage II,
35.1% for stage III, and no patients survive up to 3
years in patients with epithelial ovarian cancer stage
IV. Early detection of ovarian cancer is very necessary
because ovarian cancer that is found and treated at an
early stage had better prognosis andsurvival compared
with ovarian cancer treated at an advanced stage.
REFERENCES
1. Rasjidi I. Epidemiologi Kanker pada Wanita.
Jakarta: Sagung Seto; 2010. p. 289-349.
2. Epithelial Ovarian Cancer. Available from http://
www.who.int/entity/selection_medicines/committe
es/expert/20/applications/EpithelialOvarian.pdf?ua
=1. 2014. Accessed 16 Jul 2016.
3. Estimated Cancer Incidence, Mortality and
Prevalence Wordlwide in 2012. Available from
http://globocan.iarc.fr/Default.aspx. 2012. Access-
ed 10 Jul 2016.
4. Busmar B. Kanker Ovarium. Dalam: Aziz MF,
Andrijono, Saifuddin AB. Onkologi Ginekologi.
Jakarta: Yayasan Bina Pustaka Sarwono Prawiro-
hardjo; 2006. hal. 468-525.
5. Rasjidi I. Deteksi Dini dan Pencegahan Kanker
pada Wanita. Jakarta: Sagung Seto; 2009. hal. 183-
201.
6. Nurrika D. Analisis Ketahanan Hidup Lima Tahun
Pasien Kanker Ovarium Epithelial di Rumah Sakit
Damayanti et al. : Three years survival rate of epithelial ovarian cancer patients in Dr. Kariadi Hospital
104
Kanker Dharmais Jakarta. Tesis. Jakarta: Univer-
sitas Indonesia. 2010.
7. Ovarian Cancer Survival Statistic. Available from
http://www.cancerresearchuk.org/health professio-
nal/ cancer-statistics/ statistics-by-cancer-type/
ovarian-cancer/survival#heading-Zero. 2014.
Accessed 10 Jul 2016.
8. Grann AF, Mette N, Jan B, Erik SA, Jacob BJ.
Survival of patients with ovarian cancer in central
and northern Denmark. Clinical Epidemiology.
2011;21(1-3):59-64.
9. Sriplung H and Prechavittayakul P. Cancer
survival in Songkhla, Thailand, dalam Sankarana-
rayanan R and R Swaminathan. Cancer survival in
Africa, Asia, the Caribbean and Central America.
Lyon: International Agency for Research on
Cancer. 2011:227-35.
10. Zarchi MK, Seyed MRM, Nasrollah B, Neda Z,
Mahbube Z, Pouria YA, et al. The clinicopatho-
logic characteristics and 5-year survival rate of
epithelial ovarian cancer in Yazd, Iran. Electronic
Physician. 2015;7(6):1399-406.
11. Bamias A, Sotiropoulou M, Zagouri F, Trachana
P, Sakellariou K, Kostouros E, et al. Prognostic
evaluation of tumour type and other histopatho-
logical characteristics in advanced epithelial
ovarian cancer, treated with surgery and paclitaxel/
carboplatin chemotherapy: cell type is the most
useful prognostic factor. European Journal of
Cancer. 2011;48:1476-83.
12. Fader AN, Java J, Ueda S, Bristow RE, Armstrong
DK, Bookman MA, et al. Survival in women with
grade 1 serous ovarian carcinoma. Obstetrics &
Gynecology. 2013;122(2).
13. Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L,
Colombo N, Landoni F, et al. Role of maximal
primary cytoreductive surgery in patients with
advanced epithelial ovarian and tubal cancer:
surgical and oncological outcomes. Gynecol
Oncol. 2010;119(2):259-64.
14. Polterauer S, Vergote I, Concin N, Braicu I,
Chekerov R, Mahner S, et al. Prognostic value of
residual tumor size in patients with epithelial
ovarian cancer FIGO stages IIA-IV. International
Journal of Gynecological Cancer. 2012;22(3):380-
5.
15. Lutgendorf SK, Geest KD, Bender D, Ahmed A,
Goodheart MJ, Dahmoush L, et al. Social influen-
ces on clinical outcomes of patients with ovarian
cancer. Journal of Clinical Oncology. 2012;30:
2885-90.
16. Adrijono. Sinopsis Kanker Ginekologi. Jakarta:
Balai Penerbit Fakultas Kedokteran Universitas
Indonesia; 2013. hal. 87-287.
17. Jihong L. Tumor Ganas Ovarium, dalam Wan
Desen. Buku Ajar Onkologi Klinis. Edisi ke-2.
Jakarta: Balai Penerbit FKUI; 2011. hal. 517-26.
18. Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin
MC, You SL, et al. Trends in incidence and survi-
val outcome of epithelial ovarian cancer: 30-year
national population-based registry in Taiwan. J
Gynecol Oncol. 2013;24(4):342-51.
19. Trillsch F, Woelber L, Eulenburg C, Braicu I,
Lambrechts S, Chekerov R, et al. Treatment reality
in elderly patients with advanced ovarian cancer: a
prospective analysis of the OVCAD consortium.
Journal of Ovarian Research. 2013;6.
